Expression profiling of the ovarian surface kinome reveals candidate genes for early neoplastic changes.

OBJECTIVES We tested the hypothesis that co-coordinated up-regulation or down-regulation of several ovarian cell surface kinases may provide clues for better understanding of the disease and help in rational design of therapeutic targets. STUDY DESIGN We compared the expression signature of 69 surface kinases in normal ovarian surface epithelial cells (OSE), with OSE from patients at high risk and with ovarian cancer. RESULTS Seven surface kinases, ALK, EPHA5, EPHB1, ERBB4, INSRR, PTK, and TGFbetaR1 displayed a distinctive linear trend in expression from normal, highrisk, and malignant epithelium. We confirmed these results using semiquantitative reverse transcription-polymerase chain reaction and tissue array of 202 ovarian cancer samples. A strong correlate was shown between disease-free survival and the expression of ERBB4. DNA sequencing revealed two novel mutations in ERBB4 in two cancer samples. CONCLUSIONS A distinct subset of the ovarian surface kinome is altered in the transition from high risk to invasive cancer and genetic mutation is not a dominant mechanism for these modifications. These results have significant implications for early detection and targeted therapeutic approaches for women at high risk of developing ovarian cancer.

[1]  J. Smyth,et al.  Expression of erbB-4/HER-4 growth factor receptor isoforms in ovarian cancer. , 2001, Cancer research.

[2]  Kathleen R. Cho,et al.  Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. , 2002, Cancer research.

[3]  Andrew W Boyd,et al.  Over-expression of Eph and ephrin genes in advanced ovarian cancer: ephrin gene expression correlates with shortened survival , 2006, BMC Cancer.

[4]  J. R. Reeves,et al.  Expression of the HER1–4 family of receptor tyrosine kinases in breast cancer , 2003, The Journal of pathology.

[5]  D. Barnes,et al.  Nuclear expression of the c-erbB-4/HER-4 growth factor receptor in invasive breast cancers. , 2000, Cancer research.

[6]  Robert C. Bast,et al.  Selection of Potential Markers for Epithelial Ovarian Cancer with Gene Expression Arrays and Recursive Descent Partition Analysis , 2004, Clinical Cancer Research.

[7]  M. van de Rijn,et al.  Distinction between serous tumors of low malignant potential and serous carcinomas based on global mRNA expression profiling. , 2005, Gynecologic oncology.

[8]  L. Marrero,et al.  Presenilin-dependent γ-Secretase Processing Regulates Multiple ERBB4/HER4 Activities* , 2005, Journal of Biological Chemistry.

[9]  A. Sood,et al.  EphA2 overexpression promotes ovarian cancer growth , 2008, Cancer biology & therapy.

[10]  H Sugimura,et al.  Overexpression of ERK, an EPH family receptor protein tyrosine kinase, in various human tumors. , 1994, Cancer research.

[11]  Kathleen R. Cho,et al.  Fibroblast growth factor 9 has oncogenic activity and is a downstream target of Wnt signaling in ovarian endometrioid adenocarcinomas. , 2006, Cancer research.

[12]  Jeffrey R Marks,et al.  Gene Expression Patterns That Characterize Advanced Stage Serous Ovarian Cancers , 2004, The Journal of the Society for Gynecologic Investigation: JSGI.

[13]  Jeremy J. W. Chen,et al.  GENE EXPRESSION PROFILES IN HYPOXIC PRECONDITIONING USING CDNA MICROARRAY ANALYSIS: ALTERED EXPRESSION OF AN ANGIOGENIC FACTOR, CARCINOEMBRYONIC ANTIGEN-RELATED CELL ADHESION MOLECULE 1 , 2005, Shock.

[14]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[15]  J. Kononen,et al.  Tissue microarrays for high-throughput molecular profiling of tumor specimens , 1998, Nature Medicine.

[16]  T. Barrette,et al.  ONCOMINE: a cancer microarray database and integrated data-mining platform. , 2004, Neoplasia.

[17]  W. Park,et al.  Somatic mutations of the ERBB4 kinase domain in human cancers , 2006, International journal of cancer.

[18]  M. Ashburner,et al.  Gene Ontology: tool for the unification of biology , 2000, Nature Genetics.

[19]  D. Lockhart,et al.  Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[20]  P. Beuzeboc,et al.  Targeting HER2 in other tumor types. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  M. Essig,et al.  Dominant-negative inhibition of the Axl receptor tyrosine kinase suppresses brain tumor cell growth and invasion and prolongs survival. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[22]  S. Levy,et al.  Sequence survey of receptor tyrosine kinases reveals mutations in glioblastomas. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[23]  Jeffrey T. Chang,et al.  Oncogenic pathway signatures in human cancers as a guide to targeted therapies , 2006, Nature.

[24]  L. Caskey,et al.  HER4 Mediates Ligand-Dependent Antiproliferative and Differentiation Responses in Human Breast Cancer Cells , 2001, Molecular and Cellular Biology.